Usefulness of the Aldosterone Synthase Gene Polymorphism C-344-T to Predict Cardiac Remodeling in African-Americans Versus Non-African-Americans With Chronic Systolic Heart Failure

American Journal of Cardiology

Volumn 100, Issue 2, 2007, Pages 285-290

  Biolo, Andreia ^a   Chao, Tania ^a   Duhaney, Toni Ann S ^a   Kotlyar, Eugene ^a   Allensworth Davies, Donald ^b   Loscalzo, Joseph ^c   Sam, Flora ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CYTOSINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LABETALOL; LISINOPRIL; LOSARTAN; METOPROLOL; NITRATE; SIMVASTATIN; SPIRONOLACTONE; THYMINE;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; APPARATUS; ARTICLE; DIAGNOSTIC IMAGING; DISEASE PREDISPOSITION; DRUG USE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SIZE; HEART VENTRICLE REMODELING; HORMONE ACTION; HUMAN; IMAGE ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLE; UNITED STATES;

AFRICAN AMERICANS; ALDOSTERONE; ALDOSTERONE SYNTHASE; ALLELES; CHRONIC DISEASE; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; STROKE VOLUME; VENTRICULAR REMODELING;

EID: 34447275654     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.02.097     Document Type: Article

References (30)

1. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med 345 (2001) 1689-1697
2. Struthers A.D. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Cardiol Fail 2 (1996) 47-54
3. Sun Y., Zhang J., Lu L., Chen S.S., Quinn M.T., and Weber K.T. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161 (2002) 1773-1781
4. Sam F., Xie Z., Ooi H., Kerstetter D.L., Colucci W.S., Singh M., and Singh K. Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. Am J Hypertens 17 (2004) 188-193
5. Kotlyar E., Vita J.A., Winter M.R., Awtry E.H., Siwik D.A., Keaney Jr. J.F., Sawyer D.B., Cupples L.A., Colucci W.S., and Sam F. The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure. J Cardiol Fail 12 (2006) 122-127
6. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L., and CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82 (1990) 1730-1736
7. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., and Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
8. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J., and Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
9. White P.C., and Slutsker L. Haplotype analysis of CYP11B2. Endocrinol Res 21 (1995) 437-442
10. Zhu H., Sagnella G.A., Dong Y., Miller M.A., Onipinla A., Markandu N.D., and MacGregor G.A. Contrasting associations between aldosterone synthase gene polymorphisms and essential hypertension in blacks and in whites. J Hypertens 21 (2003) 87-95
11. Kumar N.N., Benjafield A.V., Lin R.C., Wang W.Y., Stowasser M., and Morris B.J. Haplotype analysis of aldosterone synthase gene (CYP11B2) polymorphisms shows association with essential hypertension. J Hypertens 21 (2003) 1331-1337
12. Tsukada K., Ishimitsu T., Teranishi M., Saitoh M., Yoshii M., Inada H., Ohta S., Akashi M., Minami J., Ono H., Ohrui M., and Matsuoka H. Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension. J Hum Hypertens 16 (2002) 789-793
13. Yancy C.W. Heart failure in blacks: etiologic and epidemiologic differences. Curr Cardiol Rep 3 (2001) 191-197
14. Yancy C.W. Heart failure in African Americans: a cardiovascular engima. J Cardiol Fail 6 (2000) 183-186
15. Sam F., Halickman I., Vita J.A., Levitzky Y., Cupples L.A., Loscalzo J., and Allensworth-Davies D. Predictors of improved left ventricular systolic function in an urban cardiomyopathy program. Am J Cardiol 98 (2006) 1622-1626
16. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I., and Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57 (1986) 450-458
17. Sahn D.J., DeMaria A., Kisslo J., and Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58 (1978) 1072-1083
18. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., Gutgesell H., Reichek N., Sahn D., and Schnittger I. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
19. Kupari M., Hautanen A., Lankinen L., Koskinen P., Virolainen J., Nikkila H., and White P.C. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 97 (1998) 569-575
20. Takai E., Akita H., Kanazawa K., Shiga N., Terashima M., Matsuda Y., Iwai C., Miyamoto Y., Kawai H., Takarada A., and Yokoyama M. Association between aldosterone synthase (CYP11B2) gene polymorphism and left ventricular volume in patients with dilated cardiomyopathy. Heart 88 (2002) 649-650
21. McNamara D.M., Tam S.W., Sabolinski M.L., Tobelmann P., Janosko K., Taylor A.L., Cohn J.N., Feldman A.M., and Worcel M. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial. J Am Coll Cardiol 48 (2006) 1277-1282
22. Tiret L., Mallet C., Poirier O., Nicaud V., Millaire A., Bouhour J.B., Roizes G., Desnos M., Dorent R., Schwartz K., Cambien F., and Komajda M. Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. J Am Coll Cardiol 35 (2000) 29-35
23. Tiago A.D., Badenhorst D., Skudicky D., Woodiwiss A.J., Candy G.P., Brooksbank R., Sliwa K., Sareli P., and Norton G.R. An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy. Cardiovasc Res 54 (2002) 584-589
24. Dries D.L., Exner D.V., Gersh B.J., Cooper H.A., Carson P.E., and Domanski M.J. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 340 (1999) 609-616
25. Small K.M., Wagoner L.E., Levin A.M., Kardia S.L., and Liggett S.B. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347 (2002) 1135-1142
26. Hunt S.A., Baker D.W., Chin M.H., Cinquegrani M.P., Feldman A.M., Francis G.S., Ganiats T.G., Goldstein S., Gregoratos G., Jessup M.L., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38 (2001) 2101-2113
27. Pojoga L., Gautier S., Blanc H., Guyene T.T., Poirier O., Cambien F., and Benetos A. Genetic determination of plasma aldosterone levels in essential hypertension. Am J Hypertens 11 (1998) 856-860
28. Barbato A., Russo P., Siani A., Folkerd E.J., Miller M.A., Venezia A., Grimaldi C., Strazzullo P., and Cappuccio F.P. Aldosterone synthase gene (CYP11B2) C-344T polymorphism, plasma aldosterone, renin activity and blood pressure in a multi-ethnic population. J Hypertens 22 (2004) 1895-1901
29. Paillard F., Chansel D., Brand E., Benetos A., Thomas F., Czekalski S., Ardaillou R., and Soubrier F. Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population. Hypertension 34 (1999) 423-429
30. Davies E., Holloway C.D., Ingram M.C., Inglis G.C., Friel E.C., Morrison C., Anderson N.H., Fraser R., and Connell J.M. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 33 (1999) 703-707